SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Praxis Precision Medicines forecasts $10 billion in peak sales for ulixacaltamide

Praxis Precision Medicines forecasts $10 billion in peak sales for ulixacaltamide Praxis Precisi

PRAX

Related stories